Heartseed (TYO:219A) said the first patient with dilated cardiomyopathy has been dosed in a domestic trial of its catheter-administered cell therapy HS-005.
The Independent Safety Monitoring Committee approved the trial's continuation for the dilated cardiomyopathy cohort following a review of four-week post-administration data from this case, according to a Tokyo bourse filing on Friday.
The company-sponsored study aims to expand the therapy's application beyond severe heart failure from ischaemic heart disease to include dilated cardiomyopathy, enrolling 14 patients across both disease cohorts.